Black Diamond Therapeutics
IPO News: Filed S-1: Black Diamond Therapeutics, Inc. Files $100mm IPO
Black Diamond Therapeutics

Black Diamond Therapeutics, Inc.

NASDAQ:  BDTX

Size (mm):  $100.0

Bookrunners:  JPM | JEFF | COWN | CG

Major Holders:  Versant Venture Capital | New Enterprise Associates | RA Capital | Boxer Capital | Executives and Directors (CEO, David Epstein)

Description:  Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies.

Note:  Emerging Growth Company

Reference Link:  S-1